

Health Technology Assessment Program

Selected technologies 2025

Contents

- Director's selection letter
- Topic selection background information



STATE OF WASHINGTON HEALTH CARE AUTHORITY

626 8th Avenue, SE • P.O. Box 45502 • Olympia, Washington 98504-5502

July 29, 2025

To whom it may concern:

SUBJECT: Health Technology Assessment Topic Selection, 2025

As the Interim Director of the Health Care Authority, I select technologies for review by the Health Technology Clinical Committee in consultation with other agencies and the Committee itself (70.14 RCW). Technologies are selected when there are concerns about safety, efficacy or value (cost-effectiveness), when state expenditures are or could be high, and when there is adequate evidence to conduct a review. Technologies are selected for rereview when new evidence is available that could change a previous determination.

For the current selection cycle, the proposed topics were published for review and comment; the program received no public comments from interested individuals and groups during the public comment period (June 26 to July 10, 2025). Based on this review I select the following technologies for assessment:

	Primary criteria ranking				
Technology	Safety	Efficacy	Cost		
Functional neuroimaging for primary degenerative dementia and mild cognitive impairment	Medium	Medium	Medium		
New evidence identified that could change previous determination.					
Hyperbaric oxygen therapy	Medium	High	Medium		
New evidence identified that could change previous determination.					
Catheter ablation procedures for supraventricular tachyarrhythmia including atrial flutter and atrial fibrillation	Medium	Medium	High		
New evidence identified that could change previous determination.					
Intensity modulated radiation therapy	Medium	Medium	High		

New evidence identified that could change previous determination.

Upon publication of the selected list of technologies, a 30-day comment period will begin whereby any interested person or group may provide information to be considered in the review of the selected topic(s).

Should you have any questions or concerns, please contact the HTA Program at shtap@hca.wa.gov.

Sincerely,

Mary ame Siralla

MaryAnne Lindeblad, BSN, MPH Interim Director

By email

cc: Josh Morse, HTA Director, CQCT, HCA

Melanie Golob, HTA Program & FFS Operations Manager, CQCT, HCA

Valerie Hamann, HTA Program Specialist, CQCT, HCA



Health technology assessment program

Selected technology topics – 2025

Public comments accepted until **5:00 p.m., August 29, 2025**Submit all comments to: **shtap@hca.wa.gov**

Summary

The Health Care Authority (HCA) Director selects topics for review by the Health Technology Clinical Committee (HTCC). Proposed topics are identified in consultation with the participating agencies - Labor and Industries, Department of Corrections, Health Care Authority (PEBB/SEBB and Medicaid); by HTA staff; or by petition from an interested party.

The following topics have been selected for the 2026/2027 cycle. Information may be submitted for consideration in review of these topics until August 29, 2025:

- Functional Neuroimaging for Primary Degenerative Dementia and Mild Cognitive Impairment: Rereview of the determination from 2015.
- Hyperbaric Oxygen Therapy: Rereview of the determination on thermal burns from 2015.
- Catheter Ablation Procedures For Supraventricular Tachyarrhythmia Including Atrial Flutter & Atrial Fibrillation: Rereview of the determination from 2013.
- Intensity Modulated Radiation Therapy (IMRT): Rereview of the determination from 2012.

Background

The Health Technology Clinical Committee and HTA program, rely on scientific, evidence-based information about safety and effectiveness to inform decisions about selected technologies. The HTCC is an independent committee of eleven practicing health care providers appointed to review evidence regarding the safety, efficacy, and cost-effectiveness of various medical procedures and/or equipment, and to determines the conditions of coverage for state health care purchasers.

The HCA, in consultation with participating state agencies, selects technologies for review through the HTA program process. Agency leaders or their designees are liaisons between the HTA program and the participating agencies, and provide consultation on program decisions, clinical committee membership, and to recommend and prioritize technologies.

Topics considered, not proposed

- 1. Artificial disc replacement
- 2. Gene expression profile testing of cancer tissue
- 3. Intensity modulated radiation therapy
- 4. Microprocessor-controlled lower limb prosthetics
- 5. Sleep apnea diagnosis and treatment in adults
- 6. Upper endoscopy for GERD and GI symptoms
- 7. Hyperbaric oxygen for selected indications
- 8. Pharmacogenetic testing
- 9. Ultrasound for breast imaging

Selected HTA technology topics (rereview)



Rereview technologies

Technologies are considered for rereview at least once every eighteen months. All technologies with determinations beyond 18 months since the final determination previously reviewed by the Health Technology Clinical Committee (HTCC) are listed below, along with information on whether they have been selected for rereview.

Petitioners whose topic is not selected for rereview by the Interim Director of HCA may request consideration for selection of the topic by the HTCC by contacting the HTA program staff (SHTAP@hca.wa.gov).

	Technology	HTCC review history	Rereview?
1	Artificial Disc Replacement Signal search completed in 2024. New evidence does not appear to support policy changes.	HTCC first review in 2008 with a rereview in 2017. Literature scan in 2016 and 2024.	No
2	Catheter Ablation Procedures for Supraventricular Tachyarrhythmia (SVTA) Signal search completed in 2025. New evidence identified that could change previous determination.	HTCC first reviewed in 2013. Literature scan in 2025.	Yes
3	Functional Neuroimaging for Primary Degenerative Dementia and Mild Cognitive Impairment Signal search completed in 2024. New evidence identified that could change previous determination.	HTCC first reviewed in 2015. Literature scan in 2024.	Yes
4	Gene Expression Profile Testing of Cancer Tissue Signal search completed in 2024. New evidence does not appear to support policy changes.	HTCC first review in 2018. Literature scan in 2024.	No
5	Intensity Modulated Radiation Therapy (IMRT) Signal search completed in 2025. New evidence identified that could change previous determination.	HTCC first review in 2012. Literature scan in 2025.	Yes
6	Hyperbaric Oxygen Therapy (HBOT) Signal search completed in 2025. New evidence identified for thermal burns that could change previous determination.	HTCC first reviewed in 2013. Literature scan in 2025.	Yes
7	Microprocessor-Controlled Lower Limb Prosthetics Signal search completed in 2025. New evidence does not appear to support policy changes.	HTCC first review in 2012. Literature scan in 2025.	No



	Technology	HTCC review history	Rereview?
8	Sleep Apnea Diagnosis and treatment in Adults Signal search completed in 2024. New evidence does not appear to support policy changes.	HTCC first review in 2012. Literature scan in 2024.	No
9	Upper Endoscopy for GERD and GI Symptoms Signal search completed in 2025. New evidence does not appear to support policy changes.	HTCC first review in 2012. Literature scan in 2025.	No
10	Upright/Positional MRI Signal search completed in 2024. New evidence does not appear to support policy changes.	HTCC first reviewed in 2007. Literature scan conducted in 2012 and 2024.	No

For the current period, the program has not received or identified new evidence to support review of the following:

- 1. Applied Behavioral Analysis (ABA or ABA Therapy) Based Behavioral Interventions for the Treatment of Autism Spectrum Disorder, June 2011 (Decision not implemented by participating agencies due to statutory conflict)
- 2. Appropriate Imaging for Breast Cancer Screening in Special Populations, January 2015
- 3. Autologous Blood/Platelet-Rich Plasma Injections, July 2023
- 4. Bariatric surgery, May 2024
- 5. Bone Growth Stimulation, August 2009
- 6. Bone Morphogenic Proteins for Use in Lumbar Fusion, March 2012
- 7. Breast MRI, August 2010
- 8. Bronchial Thermoplasty for Asthma, May 2016
- 9. Cardiac Stents, January 2016
- 10. Carotid Artery Stenting, September 2013
- 11. Cell-Free DNA Prenatal Screening for Chromosomal Aneuploidies (cfDNA), January 2020
- 12. Cervical Spinal Fusion for Degenerative Disc Disease, March 2013
- 13. Chronic Migraine and Chronic Tension-type Headache, March 2022
- 14. Cochlear Implants: Bilateral Versus Unilateral, September 2024
- 15. Computed Tomographic Colonography (CTC), February 2008
- 16. Coronary Artery Calcium Scoring, May 2020 (signal search)
- 17. Discography, February 2008
- 18. Electrical Neural Stimulation (ENS), October 2009

Selected HTA technology topics (rereview)



- 19. Extracorporeal Membrane Oxygenation Therapy (ECMO), March 2016
- 20. Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions, March 2017
- 21. Facet Neurotomy, June 2020 (signal search)
- 22. Fecal Microbiota Transplantation, November 2016
- 23. Genomic Microarray Testing, January 2018
- 24. Hip Resurfacing, November 2013
- 25. Hip Surgery for Femoroacetabular Impingement (FAI) Syndrome, December 2023 (signal search)
- 26. Imaging for Rhinosinusitis, May 2015
- 27. Implantable Drug Delivery System for Chronic Non-Cancer Pain, August 2008
- 28. Knee Arthroscopy for Osteoarthritis of the Knee, August 2008
- 29. Lumbar Fusion for Degenerative Disc Disease, November 2015
- 30. Negative Pressure Wound Therapy (NPWT) for Home Use, November 2016
- 31. Nonpharmacologic Treatments for Treatment Resistant Depression, March 2014
- 32. Noninvasive cardiac imaging, November 2021
- 33. Peripheral Nerve Ablation for Limb Pain, January 2019
- 34. Pharmacogenetic Testing for Patients Being Treated with Oral Anticoagulants, May 2018
- 35. Pharmacogenomic Testing for Selected Conditions, January 2017
- 36. Positron Emission Tomography (PET) Scans for Lymphoma, November 2018
- 37. Proton Beam Therapy, May 2019
- 38. Routine Ultrasound for Pregnancy, November 2010
- 39. Screening & Monitoring Tests for Osteopenia/Osteoporosis, November 2014
- 40. Selected Treatments for Varicose Veins, May 2017
- 41. Spinal Cord Stimulation, May 2024
- 42. Spinal Injections, March 2016
- 43. Stem Cell Therapy for Musculoskeletal Conditions, June 2020
- 44. Stereotactic Radiation Surgery and Stereotactic Body Radiation Therapy, June 2023
- 45. Surgery for Lumbar Radiculopathy/Sciatica, May 2018
- 46. Testosterone Testing, March 2015
- 47. Tinnitus: Non-Invasive, Non-Pharmacologic Treatments, May 2020
- 48. Total Knee Arthroplasty, October 2010
- 49. Transcranial Magnetic Stimulation for Selected Conditions, March 2023



- 50. Treatments for chondral defects of the knee, September 2024
- 51. Tumor Treating Fields (Optune), November 2018 (Petition with new evidence considered by HTCC in June 2024)
- 52. Tympanostomy Tubes in Children, November 2015
- 53. Vagal Nerve Stimulation for Epilepsy and Depression, May 2020
- 54. Vertebroplasty, Kyphoplasty, and Sacroplasty, January 2025
- 55. Vitamin D Screening and Testing, November 2012
- 56. Whole Exome Sequencing, November 2019
- 57. Whole Genome Sequencing, June 202